Atlanta—Promising results from a trial of imatinib for the treatment of chronic myeloid leukemia (CML) created a stir 6 years ago at the annual meeting of the American Society of Hematology as a validation of the notion that tailoring drugs to act on a specific molecular target could destroy malignant cells while sparing normal ones (Stephenson J. JAMA. 2000;283:317-321). Now, at the society's annual meeting, held here in December, researchers announced encouraging findings on the next generation of imatinib-related drugs.
Looking Beyond Imatinib. JAMA. 2006;295(4):369-370. doi:10.1001/jama.295.4.369